Journal of Cancer Epidemiology / 2020 / Article / Tab 2

Research Article

Mortality among Cancer Patients within 90 Days of Therapy in a Tertiary Hospital, Tanzania: Is Our Pretherapy Screening Effective?

Table 2

Baseline characteristics for patients who died within 90 days.

VariablePatient identification
123456789101112

Age (years)767152436550496251515233
BMI (kg/m2)182922.225212527.723.225.222.824.820.8
Cancer typeNasopharyngeal cancerBreast cancerGIT metastatic cancerMalignant melanomaCervical cancerPancreatic cancerSinonasal cancerAdenocarcinoma of the noseCervical cancerCervical cancerLung cancerSquamous cell carcinoma of the cheek
Type of therapy
Type 1
Type 2
Type 3
5-Fluorouracil
Cisplatin
Paclitaxel
CarboplatinDocetaxel
Dexamethasone
CarboplatinCisplatin
Dacarbazine
Gemcitabine
5-Fluorouracil
Cisplatin
Radiotherapy
CisplatinCisplatin
Radiotherapy
Cisplatin
5-Fluorouracil
Docetaxel
Dexamethasone
Cisplatin
5-Fluorouracil
Dexamethasone
Stage of cancer344333442333
Baseline neutrophil (×109/L)3.5119.73.22.382.945.650.752.835.793.213.051.47
Neutrophil 1 (×109/L)2.919.82.873.921.095.171.652.65.82.252.41.2
Neutrophil 2 (×109/L)1.352.411.081.411.67.461.31.7
Neutrophil 3 (×109/L)1.133.172.69
Neutrophil 4 (×109/L)3.073.91
Neutrophil 5 (×109/L)1
Baseline Hb (g/dL)9.611.1119.910.199.110.57.310.311.49.5
Baseline WBC (×109/L)6.144.584.84.295.338.372.924.88.845.14.972.29
Karnofsky score (%)802060809070907080908070
Blood cultureNo growthNo growthNo growthNo growthNo growthNo growthNo growthNo growthNo growthNo growthS. aureusNo growth
Urine cultureNo growthP. aeruginosaNo growthNo growthNo growthNo growthNo growthNo growthNo growthNo growthNo growthE. coli
Body temperature(°C)3638.237.136.336.837.23735.235.536.735.336.8

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.